Vincerx Pharma, Inc.
VINCOTCHealthcare● Active
$0.01
+$0.00(+3.54%)
Market Cap$68831
P/E Ratio—
52W High$1.43
52W Low$0.001
Vincerx Pharma, Inc. (VINC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
VINC · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2025Report Date: May 15, 2025EPS Actual
-$0.91
Revenue
—
Fiscal Period
Q2 FY2025
FY ends December
Report Date
May 15, 2025
After Market Close
VINC reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$3.83
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$3.83
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 7, 2026 | — | — | — | — | — | — |
| ◌ Q3 FY2026 | Aug 7, 2026 | — | — | — | — | — | — |
| ◌ Q1 FY2026 | Mar 27, 2026 | -$2.20 | — | — | — | — | — |
| ◌ Q4 FY2025 | Nov 10, 2025 | — | — | — | — | — | — |
| ◌ Q3 FY2025 | Aug 28, 2025 | — | — | — | — | — | — |
| — Q2 FY2025 | May 15, 2025 | — | -$0.91 | — | — | — | — |
| ▼ Q1 FY2025 | Mar 27, 2025 | -$3.40 | -$4.20 | -23.5% | — | — | — |
| — Q4 FY2024 | Nov 12, 2024 | -$3.40 | -$3.40 | +0.0% | — | — | — |
Q3 FY2026
Aug 7, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2026
Aug 7, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 27, 2026
EPS Actual
—
EPS Est.
-$2.20
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 10, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 28, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 15, 2025
EPS Actual
-$0.91
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 27, 2025Miss
EPS Actual
-$4.20
EPS Est.
-$3.40
EPS Surpr.
-23.5%
Revenue
—
Q4 FY2024
Nov 12, 2024
EPS Actual
-$3.40
EPS Est.
-$3.40
EPS Surpr.
+0.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-2.20 | $-2.20 | $-2.20 | 1 |
| Q3 FY2025 | $-2.40 | $-2.40 | $-2.40 | 1 |
| Q2 FY2025 | $-2.40 | $-2.40 | $-2.40 | 1 |
| Q1 FY2025 | $-2.40 | $-2.40 | $-2.40 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2025 | May 15, 2025 | — | $0.05 | $0.05 | +2.04% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -23.5% | $0.60 | $0.57 | -5.97% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +0.0% | $7.04 | $6.79 | -3.55% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +70.6% | $11.08 | $11.12 | +0.36% |
| ▼ Q2 FY2024 | May 14, 2024 | -30.8% | $15.20 | $15.29 | +0.59% |
| ▲ Q1 FY2024 | Mar 29, 2024 | +45.2% | $101.20 | $117.00 | +15.61% |
| ▲ Q4 FY2023 | Nov 14, 2023 | +6.1% | $17.58 | $16.00 | -8.99% |
Q2 FY2025+2.04%
Report Date
May 15, 2025
EPS Beat/Miss
—
Price Before
$0.05
Price After
$0.05
Q1 FY2025-5.97%
Report Date
Mar 27, 2025
EPS Beat/Miss
-23.5%
Price Before
$0.60
Price After
$0.57
Q4 FY2024-3.55%
Report Date
Nov 12, 2024
EPS Beat/Miss
+0.0%
Price Before
$7.04
Price After
$6.79
Q3 FY2024+0.36%
Report Date
Aug 8, 2024
EPS Beat/Miss
+70.6%
Price Before
$11.08
Price After
$11.12
Q2 FY2024+0.59%
Report Date
May 14, 2024
EPS Beat/Miss
-30.8%
Price Before
$15.20
Price After
$15.29
Q1 FY2024+15.61%
Report Date
Mar 29, 2024
EPS Beat/Miss
+45.2%
Price Before
$101.20
Price After
$117.00
Q4 FY2023-8.99%
Report Date
Nov 14, 2023
EPS Beat/Miss
+6.1%
Price Before
$17.58
Price After
$16.00
Avg Beat Reaction+0.86%
Avg Miss Reaction-2.69%
Beat Rate4 / 7 quarters
Largest Move+15.61% (Q1 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: VINC ends December
Vincerx Pharma, Inc. (VINC) most recently reported earnings on May 15, 2025 for Q2 FY2025, posting EPS of $-0.91 (in line with the analyst consensus of —). The next VINC earnings date is expected around September 1, 2026.
Each quarter, investors track VINC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. VINC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
VINC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
VINC earnings · 4 questionsVincerx Pharma, Inc.'s next earnings report is expected around September 1, 2026. VINC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; VINC historically reports after market close (AMC).
VINC earnings datewhen is VINC earningsVINC next earnings datewhen does VINC report earningsVINC earnings calendar
▸ Source: FMP · Vincerx Pharma, Inc. SEC filings · US GAAP · Vincerx Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026